Abstract:Tamsulosin is a therapeutic drug of alpha-adrenergic antagonists. Previous randomized controlled trials and retrospective analyses have proved the efficacy of tamsulosin on many urinary system diseases. However, there is still a conflict about whether tamsulosin could prevent postoperative urinary retention (POUR). This meta-analysis aims to probe into the efficacy of tamsulosin for preventing POUR versus placebo. We searched MEDLINE, EMBASE, and Cochrane Library from December 31, 1999 to April 30, 2022, for randomized controlled trials (RCTs). Studies that were not RCTs or without negative controls were excluded. Cochrane Collaboration harmonized criteria were used to assess the risk of bias in included studies. Revman (version 5.3) software was invited to synthesize the results. We performed subgroup analyses to explore the factors that could influence tamsulosin's efficacy in POUR prevention. Our meta-analysis pooled 13 RCTs with 2163 patients. We concluded that tamsulosin brought about a significant reduction in the risk of POUR versus placebo (13.54% vs 20.88% for tamsulosin vs placebo, RR = 0.63, 95% CI 0.47 to 0.84, P = 0.002). Tamsulosin could significantly reduce the risk of POUR in abdominal (11.52% vs 20.25% for tamsulosin vs placebo, RR = 0.52, 95% CI 0.31 to 0.88, P = 0.02) and female pelvic surgery (15.57% vs 31.50% for tamsulosin vs placebo, RR = 0.51, 95% CI 0.31 to 0.82, P = 0.006) but not in spinal surgery (13.45% vs 12.75% for tamsulosin vs placebo, RR = 1.07, 95% CI 0.72 to 1.60, P = 0.73) and lower limb surgery (21.43% vs 33.33% for tamsulosin vs placebo, RR = 0.64, 95% CI 0.35 to 1.14, P = 0.13). The preventive effect of postoperative (17.70% vs 33.93% for tamsulosin vs placebo, RR = 0.53, 95% CI 0.33 to 0.85, P = 0.008) and postoperative with preoperative tamsulosin (13.96% vs 23.44% for tamsulosin vs placebo, RR = 0.64, 95% CI 0.43 to 0.93, P = 0.02) on POUR were significantly better than preoperative management (11.95% vs 14.63% for tamsulosin vs placebo, RR = 0.62, 95% CI 0.23 to 1.65, P = 0.34). Postoperative catheter placement appears to have a negative impact on the POUR-preventive effect of tamsulosin. (9.37% vs 16.46% for tamsulosin vs placebo, RR = 0.51, 95% CI 0.31 to 0.83, P = 0.007) Tamsulosin showed significantly effect on POUR prevention in patients during spinal (15.07% vs 26.51% for tamsulosin vs placebo, RR = 0.52, 95% CI 0.31 to 0.90, P = 0.02) and epidural anesthesia (12.50% vs 29.79% for tamsulosin vs placebo, RR = 0.42, 95% CI 0.18 to 1.00, P = 0.05) but not in general anesthesia (12.40% vs 18.52% for tamsulosin vs placebo, RR = 0.68, 95% CI 0.45 to 1.03, P = 0.07). Tamsulosin shows better outcomes for preventing POUR than placebo. Besides, tamsulosin showed a different effect on POUR prevention in the various surgical sites, anesthesia, medication management, and catheter use. However, our conclusions still have some limitations due to the lack of evidence.

The research of Finasteride and Tamsulosin to reduce hemorrhage during TURP

The value of transurethral cylindrical dilatation of the prostate in the treatment of patients with benign prostatic hyperplasia

High-risk benign prostatic hyperplasia patients treated with transurethral resection of prostate

[Transurethral Resection of Prostate Perioperative Hypotension]

A comparative study of two means of simultaneous treatment for benign prostate hyperplasia and bladder stone

Effect of finasteride on reducing hemorrhage in holmium lasterenucleation of prostate

Impact of Preoperative 5Α-Reductase Inhibitors on Perioperative Blood Loss in Patients with Benign Prostatic Hyperplasia: a Meta-Analysis of Randomized Controlled Trials

Effect of carbazochrome tablets combined with finasteride in reducing hematuria after electroprostatectomy

Blood loss of transurethral resection of prostate and effect of hemocoagulase usage after TURP

[The Effect of Yunnan Baiyao on Reduction of Intra-Operative Bleeding of the Patients Undergoing Transurethral Resection of Prostate].

[Cost and Effectiveness Analysis of Treatments for Benign Prostatic Hyperplasia].

Efficacy of 5Α-Reductase Inhibitors for Patients with Large Benign Prostatic Hyperplasia (>80 Ml) after Transurethral Resection of the Prostate

The Clinical Safety and Efficacy of PKRP and TURP in the Treatment of Patients with Benign Prostatic Hyperplasia Prostate(volume>60 Ml):A Compared Study

Evaluation on Safety and Efficacy of Finasteride in Treatment of Benign Prostatic Hyperplasia

The effect of tamsulosin in postoperative urinary retention: a meta-analysis of randomized controlled trials

Effects of sexual function of TURP and TUIBN

The comparison between finasteride and tamsulosin therapeutic efficacy in the treatment of symptomatic benign prostate hyperplasia

Evaluating the effectiveness of tranexamic acid administration in reducing bleeding in benign prostate hyperplasia patients underwent open prostatectomy: A double-blind randomized clinical trial

Comparative Study of the Clinical Efficacy of Transurethral Enucleation of the Prostate and Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia

Observation on Curative Efficacy of Tamsulosin Hydrochloride Sustained-Release Capsules Combined with Finasteride Tablets in the Treatment of Benign Prostatic Hyperplasia

[Transurethral columnar balloon dilation of the prostate for benign prostatic hyperplasia]